Back to Search
Start Over
Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response
- Source :
- Frontiers in Immunology, Frontiers in Immunology, Vol 12 (2021)
- Publication Year :
- 2021
- Publisher :
- Frontiers Media SA, 2021.
-
Abstract
- Vitiligo is an acquired depigmentation skin disease caused by immune-mediated death of melanocytes. The most common treatment for vitiligo is narrow band ultraviolet B phototherapy, which often is combined with topical therapies such as tacrolimus. However, patients’ responses to these treatments show large variations. To date, the mechanism for this heterogeneity is unknown, and there are no molecular indicators that can predict an individual patient’s response to therapy. The goal of this study is to identify clinical parameters and gene expression biomarkers associated with vitiligo response to therapy. Six patients with segmental vitiligo and 30 patients with non-segmental vitiligo underwent transcriptome sequencing of lesional and nonlesional skin at baseline before receiving combined UBUVB and tacrolimus therapy for 6 month, and were separated into good response and bad response groups based on target lesion achieving > 10% repigmentation or not. Our study revealed that treatment-responsive vitiligo lesions had significantly shorter disease duration compared with non-responsive vitiligo lesions (2.5 years vs 11.5 years, p=0.046, t-Test), while showing no significant differences in the age, gender, ethnicity, vitiligo subtype, or disease severity. Transcriptomic analyses identified a panel of 68 genes separating the good response from bad response lesions including upregulation of immune active genes, such as CXCL10, FCRL3, and TCR, Further, compared with vitiligo lesions with long disease duration, the lesions with short duration also have much higher level of expression of immune-active genes, including some (such as FCRL3 and TCR genes) that are associated with favorable therapeutic response. In conclusion, our study has identified clinical parameters such as short disease duration and a panel of immune active and other gene expression biomarkers that are associated with favorable response to immune suppressive NBUVB + tacrolimus therapy. These markers may be useful clinically for individualized therapeutic management of vitiligo patients in the future.
- Subjects :
- lcsh:Immunologic diseases. Allergy
Adult
Male
vitiligo
0301 basic medicine
Target lesion
medicine.medical_specialty
Biopsy
Immunology
Vitiligo
Disease
Transcriptome
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Immune system
response to therapy
Humans
Immunology and Allergy
Medicine
CXCL10
tacrolimus
skin and connective tissue diseases
Aged
Original Research
integumentary system
business.industry
Gene Expression Profiling
T-cell receptor
Computational Biology
Disease Management
biomarkers
RNA sequencing
Middle Aged
medicine.disease
Combined Modality Therapy
Dermatology
Tacrolimus
Treatment Outcome
030104 developmental biology
Case-Control Studies
Female
Disease Susceptibility
lcsh:RC581-607
business
phototherapy
therapeutic markers
Subjects
Details
- ISSN :
- 16643224
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Frontiers in Immunology
- Accession number :
- edsair.doi.dedup.....2777e5353e96263d5879f3f96f99c988